ABUS - アルブ―タス・バイオファ―マ （Arbutus Biopharma Corporation） アルブ―タス・バイオファ―マABUSのチャート
ABUSの企業情報
| symbol | ABUS |
|---|---|
| 会社名 | Arbutus Biopharma Corp （アルブ―タス・バイオファ―マ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Arbutus Biopharma Corp is a Canada-based biopharmaceutical company. The Company is dedicated to discovering developing and commercializing a cure for patients suffering from chronic hepatitis B infection a disease of the liver caused by hepatitis B virus (HBV). The Company develops a portfolio of drug candidates with multiple mechanisms of action that results in a combination therapy to cure HBV. In addition to its HBV pipeline the Company actively licenses its Lipid Nanoparticle (LNP) technology to its industry partners. This technology represents a delivery technology in RNA interference (RNAi) therapeutic development which has enabled several clinical trials and has been administered to hundreds of human subjects. アルブ―タス・バイオファ―マはカナダのバイオ医薬品企業。主に先進リボ核酸(RNA)干渉(RNAi)治療薬の研究開発に取り組み、製薬企業パ―トナ―に脂質ナノ粒子送達技術を提供する。慢性B型肝炎感染の患者に特化し、B型肝炎ウイルス(HBV)による肝臓疾患に対する治療法の発見、開発、商業化に従事する。本社はブリティッシュコロンビア州。 Arbutus Biopharma Corporation is a biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). |
| 本社所在地 | 100-8900 Glenlyon Parkway Burnaby British Columbia V5J 5J8 CAN |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +1 604-419-3200 |
| 設立年月日 | 38626 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 130人 |
| url | www.arbutusbio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/abus |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -66.20400 |
| 終値（lastsale） | 9.11 |
| 時価総額（marketcap） | 504733154.78 |
| 時価総額 | 時価総額（百万ドル） 332.42580 |
| 売上高 | 売上高（百万ドル） 12.10600 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 298.47880 |
| 当期純利益 | 当期純利益（百万ドル） -84.55700 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Arbutus Biopharma Corp revenues increased from $1.3M to $2.7M. Net loss applicable to common stockholders decreased 48% to $19.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Gain on investment increase from $0K to $24.9M (income). |
ABUSのテクニカル分析
ABUSのニュース
What''s the Outlook for Arbutus Biopharma? 2022/02/05 13:55:00 The Motley Fool
The company could have great prospects if its hepatitis B virus therapy is successful in clinical testing.
Arbutus Biopharma outlines milestones for 2022 2022/01/24 13:12:35 Seeking Alpha
Arbutus Biopharma (ABUS) announces its 2022 corporate objectives and provided a financial update
Stock is blowing up: Arbutus Biopharma Corporation (NASDAQ:ABUS), Banco Santander, S.A. (NYSE:SAN) 2021/12/24 00:00:21 Stock Equity
Arbutus Biopharma Corporation (NASDAQ:ABUS) with the stream of 0.00% also noticed, India Banco Santander, S.A. (NYSE:SAN) encountered a rapid change of 2.84% in the last hour of Thursdays trading session. The post Stock is blowing up: Arbutus Biopharma Corporation (NASDAQ:ABUS), Banco Santander, S.A. (NYSE:SAN) appeared first on Stocks Equity .
Arbutus Biopharma (NASDAQ:ABUS) Shares Down 2.9% 2021/12/23 17:38:42 Transcript Daily
Arbutus Biopharma Co. (NASDAQ:ABUS) traded down 2.9% during trading on Thursday . The company traded as low as $4.00 and last traded at $4.04. 60,266 shares traded hands during mid-day trading, a decline of 100% from the average session volume of 25,955,150 shares. The stock had previously closed at $4.16. A number of equities research []
RNAi for Therapeutic Market 2021 Precise Outlook - Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead 2021/12/23 08:45:18 OpenPR
The "RNAi for Therapeutic" Market report offers qualitative and quantitative insights and a detailed analysis of market size & growth rate for all possible segments in the market. The Global RNAi for Therapeutic Industry presents a market overview, product details,
Stock is blowing up: Arbutus Biopharma Corporation (NASDAQ:ABUS), Banco Santander, S.A. (NYSE:SAN) 2021/12/24 00:00:21 Stock Equity
Arbutus Biopharma Corporation (NASDAQ:ABUS) with the stream of 0.00% also noticed, India Banco Santander, S.A. (NYSE:SAN) encountered a rapid change of 2.84% in the last hour of Thursdays trading session. The post Stock is blowing up: Arbutus Biopharma Corporation (NASDAQ:ABUS), Banco Santander, S.A. (NYSE:SAN) appeared first on Stocks Equity .
Arbutus Biopharma (NASDAQ:ABUS) Shares Down 2.9% 2021/12/23 17:38:42 Transcript Daily
Arbutus Biopharma Co. (NASDAQ:ABUS) traded down 2.9% during trading on Thursday . The company traded as low as $4.00 and last traded at $4.04. 60,266 shares traded hands during mid-day trading, a decline of 100% from the average session volume of 25,955,150 shares. The stock had previously closed at $4.16. A number of equities research []
RNAi for Therapeutic Market 2021 Precise Outlook - Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead 2021/12/23 08:45:18 OpenPR
The "RNAi for Therapeutic" Market report offers qualitative and quantitative insights and a detailed analysis of market size & growth rate for all possible segments in the market. The Global RNAi for Therapeutic Industry presents a market overview, product details,
Brokerages Expect Arbutus Biopharma Co. (NASDAQ:ABUS) to Post -$0.18 Earnings Per Share 2021/12/15 22:52:41 Transcript Daily
Equities analysts expect Arbutus Biopharma Co. (NASDAQ:ABUS) to announce earnings of ($0.18) per share for the current quarter, Zacks reports. Two analysts have made estimates for Arbutus Biopharmas earnings, with the highest EPS estimate coming in at ($0.16) and the lowest estimate coming in at ($0.19). Arbutus Biopharma reported earnings per share of ($0.23) in []
Analysts Anticipate Arbutus Biopharma Co. (NASDAQ:ABUS) Will Post Quarterly Sales of $3.39 Million 2021/12/15 22:52:41 Dakota Financial News
Equities research analysts expect Arbutus Biopharma Co. (NASDAQ:ABUS) to report sales of $3.39 million for the current quarter, Zacks reports. Two analysts have issued estimates for Arbutus Biopharmas earnings, with the highest sales estimate coming in at $3.47 million and the lowest estimate coming in at $3.30 million. Arbutus Biopharma posted sales of $2.39 million []
Arbutus Biopharma (NASDAQ:ABUS) Sees Unusually-High Trading Volume 2021/12/01 15:50:42 Transcript Daily
Arbutus Biopharma Co. (NASDAQ:ABUS) shares saw strong trading volume on Wednesday . 814,409 shares changed hands during trading, a decline of 61% from the previous sessions volume of 2,086,054 shares.The stock last traded at $4.40 and had previously closed at $3.20. A number of equities analysts have weighed in on the stock. HC Wainwright reduced []
Nuveen Asset Management LLC Takes Position in Arbutus Biopharma Co. (NASDAQ:ABUS) 2021/11/30 09:22:43 Dakota Financial News
Nuveen Asset Management LLC bought a new stake in shares of Arbutus Biopharma Co. (NASDAQ:ABUS) in the 2nd quarter, Holdings Channel reports. The fund bought 226,012 shares of the biopharmaceutical companys stock, valued at approximately $685,000. Several other institutional investors have also made changes to their positions in ABUS. Northern Trust Corp grew its stake []
Northern Trust Corp Has $2.18 Million Stock Position in Arbutus Biopharma Co. (NASDAQ:ABUS) 2021/11/26 09:32:41 Dakota Financial News
Northern Trust Corp raised its position in Arbutus Biopharma Co. (NASDAQ:ABUS) by 441.9% in the second quarter, HoldingsChannel reports. The fund owned 719,159 shares of the biopharmaceutical companys stock after purchasing an additional 586,456 shares during the quarter. Northern Trust Corps holdings in Arbutus Biopharma were worth $2,179,000 as of its most recent SEC filing. []
Arbutus Biopharma Corporation (NASDAQ: ABUS) Stock Dropped -21.62% Over A Month Are There Any Chances Of Growth? 2021/11/25 15:00:00 Marketing Sentinel
During the last session, Arbutus Biopharma Corporation (NASDAQ:ABUS)s traded shares were 0.72 million, with the beta value of the company hitting 2.58. At the end of the trading day, the stocks price was $3.19, reflecting an intraday gain of 2.24% or $0.07. The 52-week high for the ABUS share is $5.87, that puts it down Arbutus Biopharma Corporation (NASDAQ: ABUS) Stock Dropped -21.62% Over A Month Are There Any Chances Of Growth? Read More »
Analysts Expect Arbutus Biopharma Co. (NASDAQ:ABUS) to Post -$0.18 EPS 2021/11/21 12:46:44 Dakota Financial News
Brokerages expect Arbutus Biopharma Co. (NASDAQ:ABUS) to post ($0.18) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Arbutus Biopharmas earnings, with the highest EPS estimate coming in at ($0.16) and the lowest estimate coming in at ($0.19). Arbutus Biopharma reported earnings per share of []